TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: System-integrated Technology-enabled Model of Care to Improve the Health of Stroke Patients in Rural China
Brief Summary: Despite the significant burden of stroke in rural China, secondary prevention of stroke is scarce. The aim of the study is to develop a system-integrated technology-enabled intervention (SINEMA) model for the secondary prevention of stroke in rural China and evaluate the effectiveness of the model compared with usual care. The hypothesis is that trained village doctors, equipped with digital health technology, can provide essential evidence-based care to stroke survivors in rural China.


Options:
A: Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Procedure: Ophthalmic Telemedicine | Arm Label: Traditional Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Ophthalmic Telemedicine; Assigned to Arm(s): Telemedicine
B: Arm Label: SINEMA intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: SINEMA intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SINEMA intervention; Assigned to Arm(s): SINEMA intervention group
C: Arm Label: Tertiary care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Primary care; Type: EXPERIMENTAL; Interventions: Other: Telemedicine | Intervention Type: OTHER; Name: Telemedicine; Assigned to Arm(s): Primary care
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Procedure: Store and forward teledermatology | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Store and forward teledermatology; Assigned to Arm(s): Arm 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Antithrombotic Treatment After IntraCerebral Haemorrhage
Brief Summary: The study evaluates the effects of antithrombotic drugs (anticoagulant drugs or antiplatelet drugs) for prevention of ischaemic events in patients With recent intracerebral haemorrhage.


Options:
A: Arm Label: Apixaban; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Avoiding oral anticoagulants; Type: OTHER; Interventions: Drug: Aspirin, Drug: Carbasalate calcium, Drug: Clopidogrel, Drug: Dipyridamole, Other: No antithrombotic treatment | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Avoiding oral anticoagulants | Intervention Type: DRUG; Name: Carbasalate calcium; Assigned to Arm(s): Avoiding oral anticoagulants | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Avoiding oral anticoagulants | Intervention Type: DRUG; Name: Dipyridamole; Assigned to Arm(s): Avoiding oral anticoagulants | Intervention Type: OTHER; Name: No antithrombotic treatment; Assigned to Arm(s): Avoiding oral anticoagulants
B: Arm Label: Antithrombotic treatment; Type: EXPERIMENTAL; Interventions: Drug: Antithrombotic Agent | Arm Label: No antithrombotic treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Antithrombotic Agent; Assigned to Arm(s): Antithrombotic treatment
C: Arm Label: Telemetric Bluetooth-enabled home BP monitors; Type: EXPERIMENTAL; Interventions: Device: A&D BP Digital Blood Pressure Monitor (UA-767PBT-Ci) CE Declaration UA-767PBT-Ci | Arm Label: Standard clinical care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: A&D BP Digital Blood Pressure Monitor (UA-767PBT-Ci) CE Declaration UA-767PBT-Ci; Assigned to Arm(s): Telemetric Bluetooth-enabled home BP monitors
D: Arm Label: low weight molecular heparin; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin | Arm Label: standard therapy; Type: PLACEBO_COMPARATOR; Interventions: Other: Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): low weight molecular heparin | Intervention Type: OTHER; Name: Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization; Assigned to Arm(s): standard therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transcutaneous Electrical Nerve Stimulation (TENS) for Pain Control During First Trimester Abortion: A Blinded Randomized Controlled Trial
Brief Summary: High-frequency, high-intensity transcutaneous electrical nerve-stimulation (TENS) is an inexpensive and non-invasive pain control approach. TENS, pulsating electrical currents that activate underlying nerves, does not have drug interactions or risk of overdose. Cochrane review of TENS for acute pain found inconclusive evidence. One previous abortion trial comparing TENS to IV sedation only looked at pain control in the recovery room. The investigators propose a randomized controlled trial comparing TENS to IV sedation (in conjunction with local anesthesia) among women presenting for first-trimester surgical abortion. Primary outcome will be perceived pain by Visual Analogue Scale (VAS) during aspiration.


Options:
A: Arm Label: paracervical block with lidocaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: lidocaine | Arm Label: paracervical block with ketorolac and lidocaine; Type: EXPERIMENTAL; Interventions: Drug: ketorolac and lidocaine | Intervention Type: DRUG; Name: lidocaine; Assigned to Arm(s): paracervical block with lidocaine | Intervention Type: DRUG; Name: ketorolac and lidocaine; Assigned to Arm(s): paracervical block with ketorolac and lidocaine
B: Arm Label: Transcutaneous electrical nerve stimulation (TENS); Type: EXPERIMENTAL; Interventions: Device: Transcutaneous electrical nerve stimulation (TENS), Other: SHAM: Moderate IV Sedation | Arm Label: Moderate IV Sedation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Moderate IV Sedation, Other: SHAM: Transcutaneous electrical nerve stimulation (TENS) | Intervention Type: DEVICE; Name: Transcutaneous electrical nerve stimulation (TENS); Assigned to Arm(s): Transcutaneous electrical nerve stimulation (TENS) | Intervention Type: DRUG; Name: Moderate IV Sedation; Assigned to Arm(s): Moderate IV Sedation | Intervention Type: OTHER; Name: SHAM: Transcutaneous electrical nerve stimulation (TENS); Assigned to Arm(s): Moderate IV Sedation | Intervention Type: OTHER; Name: SHAM: Moderate IV Sedation; Assigned to Arm(s): Transcutaneous electrical nerve stimulation (TENS)
C: Arm Label: Active Comparator; Type: EXPERIMENTAL; Interventions: Drug: vaginal 2% Xylocaine | Arm Label: standard lidocaine paracervical block; Type: OTHER; Interventions: Drug: standard lidocaine paracervical block | Intervention Type: DRUG; Name: vaginal 2% Xylocaine; Assigned to Arm(s): Active Comparator | Intervention Type: DRUG; Name: standard lidocaine paracervical block; Assigned to Arm(s): standard lidocaine paracervical block
D: Intervention Type: DRUG; Name: oxycodone + lorazepam versus fentanyl + midazolam; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Chamas for Change: Validating an Integrated Community-based Strategy of Peer Support in Pregnancy and Infancy in Kenya
Brief Summary: This team has shown that chamas can be tailored to increase the uptake of health services in pregnancy and infancy, sustain themselves beyond the period of funding and become integrated within a county's health strategy. However, further investment is warranted to validate this intervention in a new region to ensure the positive effects on MNCH are a result of chamas and can be replicated. The purpose of this study is to demonstrate that chamas are an effective service-delivery platform for improving women's and children's health and well-being in western Kenya.


Options:
A: Arm Label: Philani Intervention Model+MOVIE (PIM+M); Type: EXPERIMENTAL; Interventions: Behavioral: Philani Intervention Model+MOVIE (PIM+M) | Arm Label: Philani Intervention Model (PIM); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Philani Intervention Model (PIM) | Intervention Type: BEHAVIORAL; Name: Philani Intervention Model+MOVIE (PIM+M); Assigned to Arm(s): Philani Intervention Model+MOVIE (PIM+M) | Intervention Type: BEHAVIORAL; Name: Philani Intervention Model (PIM); Assigned to Arm(s): Philani Intervention Model (PIM)
B: Arm Label: Two-way SMS; Type: EXPERIMENTAL; Interventions: Behavioral: Two-way SMS | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Two-way SMS; Assigned to Arm(s): Two-way SMS
C: Arm Label: Chama cha MamaToto; Type: EXPERIMENTAL; Interventions: Behavioral: Chama cha MamaToto | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Chama cha MamaToto; Assigned to Arm(s): Chama cha MamaToto
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Simple Intervention; Type: EXPERIMENTAL; Interventions: Other: HIV testing commodity reinforcement, Other: Policy reinforcement meeting | Arm Label: Comprehensive Intervention; Type: EXPERIMENTAL; Interventions: Other: HIV testing commodity reinforcement, Other: Policy reinforcement meeting, Other: Opt-out HIV testing for mothers and newborns, Other: Operational support for service integration, Other: Community sensitization | Intervention Type: OTHER; Name: HIV testing commodity reinforcement; Assigned to Arm(s): Comprehensive Intervention, Simple Intervention | Intervention Type: OTHER; Name: Policy reinforcement meeting; Assigned to Arm(s): Comprehensive Intervention, Simple Intervention | Intervention Type: OTHER; Name: Opt-out HIV testing for mothers and newborns; Assigned to Arm(s): Comprehensive Intervention | Intervention Type: OTHER; Name: Operational support for service integration; Assigned to Arm(s): Comprehensive Intervention | Intervention Type: OTHER; Name: Community sensitization; Assigned to Arm(s): Comprehensive Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Respiratory Muscle Training in Patients With Cystic Fibrosis
Brief Summary: The present study aims at evaluating the effect of respiratory muscle training in adult patients with cystic fibrosis on lung function, exercise performance and quality of life.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Wellness | Intervention Type: BEHAVIORAL; Name: Physical activity; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Wellness; Assigned to Arm(s): 2
B: Arm Label: ACTs after HTS inhalation:; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Arm Label: ACTs during HTS inhalation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Intervention Type: PROCEDURE; Name: Airways clearance and Hypertonic saline inhalation; Assigned to Arm(s): ACTs after HTS inhalation:, ACTs during HTS inhalation
C: Arm Label: Endurance respiratory muscle training; Type: EXPERIMENTAL; Interventions: Other: Endurance respiratory muscle training | Arm Label: Resistance inspiratory muscle training; Type: ACTIVE_COMPARATOR; Interventions: Other: Resistance inspiratory muscle training | Intervention Type: OTHER; Name: Endurance respiratory muscle training; Assigned to Arm(s): Endurance respiratory muscle training | Intervention Type: OTHER; Name: Resistance inspiratory muscle training; Assigned to Arm(s): Resistance inspiratory muscle training
D: Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional chest physiotherapy | Arm Label: Training Group; Type: EXPERIMENTAL; Interventions: Other: Conventional chest physiotherapy, Other: Inspiratory muscle training | Intervention Type: OTHER; Name: Conventional chest physiotherapy; Assigned to Arm(s): Control Group, Training Group | Intervention Type: OTHER; Name: Inspiratory muscle training; Assigned to Arm(s): Training Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Build Our Kids' Success (BOKS) Before-school Physical Activity Program
Brief Summary: BOKS, Build Our Kids' Success, is a before-school physical activity program that has been implemented in over 2,000 elementary and middle schools. Students participate in the program for 12 weeks, two or three mornings per week for about 1 hour per session. This study if a non-randomized control trial seeking to 1) examine the extent to which participation in the before-school BOKS program improves, health, well-being, and performance, and 2) compare the results of a two-day-per-week versus a three-day-per-week program.


Options:
A: Arm Label: Physical Activity Only; Type: EXPERIMENTAL; Interventions: Other: OPPORTUNITIES FOR PHYSICAL ACTIVITY | Arm Label: Delayed Interventions Only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Nutrition and Physical Activity; Type: EXPERIMENTAL; Interventions: Other: DISTRICT WELLNESS COMMITTEE, Other: NUTRITIONAL QUALITY OF FOODS AND BEVERAGES ON CAMPUS, Other: HEALTH PROMOTION AND MARKETING, Other: OPPORTUNITIES FOR PHYSICAL ACTIVITY | Arm Label: Nutrition Only Interventions; Type: EXPERIMENTAL; Interventions: Other: NUTRITIONAL QUALITY OF FOODS AND BEVERAGES ON CAMPUS | Intervention Type: OTHER; Name: DISTRICT WELLNESS COMMITTEE; Assigned to Arm(s): Nutrition and Physical Activity | Intervention Type: OTHER; Name: NUTRITIONAL QUALITY OF FOODS AND BEVERAGES ON CAMPUS; Assigned to Arm(s): Nutrition Only Interventions, Nutrition and Physical Activity | Intervention Type: OTHER; Name: HEALTH PROMOTION AND MARKETING; Assigned to Arm(s): Nutrition and Physical Activity | Intervention Type: OTHER; Name: OPPORTUNITIES FOR PHYSICAL ACTIVITY; Assigned to Arm(s): Nutrition and Physical Activity, Physical Activity Only
B: Arm Label: The Health Lifestyles Interventions; Type: EXPERIMENTAL; Interventions: Behavioral: The Health Lifestyles Interventions | Arm Label: Receive no intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: The Health Lifestyles Interventions; Assigned to Arm(s): The Health Lifestyles Interventions
C: Arm Label: BOKS: 2 day per week; Type: EXPERIMENTAL; Interventions: Behavioral: BOKS: 2 day a week before-school physical activity program | Arm Label: BOKS: 3 day per week; Type: EXPERIMENTAL; Interventions: Behavioral: BOKS: 3 day a week before-school physical activity program | Arm Label: Non-BOKS; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: BOKS: 2 day a week before-school physical activity program; Assigned to Arm(s): BOKS: 2 day per week | Intervention Type: BEHAVIORAL; Name: BOKS: 3 day a week before-school physical activity program; Assigned to Arm(s): BOKS: 3 day per week
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: CHAM JAM | Arm Label: Wait-Listed Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: CHAM JAM; Assigned to Arm(s): Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression (CREST - MST)
Brief Summary: This trial aims to assess the efficacy and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for depression. Even with multiple medication trials, 30 - 40% of patients will experience a pharmacologically resistant form of illness. The ineffectiveness of current treatments for major depressive disorder (MDD) coupled with the economic burden associated with the disorder engenders a need for novel therapeutic interventions that can provide greater response and remission rates.


Options:
A: Arm Label: Magnetic seizure therapy; Type: EXPERIMENTAL; Interventions: Device: Magnetic seizure therapy | Arm Label: Electroconvulsive therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Electroconvulsive therapy | Intervention Type: DEVICE; Name: Magnetic seizure therapy; Assigned to Arm(s): Magnetic seizure therapy | Intervention Type: DEVICE; Name: Electroconvulsive therapy; Assigned to Arm(s): Electroconvulsive therapy
B: Arm Label: magnetic seizure therapy; Type: EXPERIMENTAL; Interventions: Device: Magpro X100 + Option, Other: treatment as usual (TAU) | Arm Label: electroconvulsive therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: ThymatronSystem Ⅳ Electroconvulsive System, Other: treatment as usual (TAU) | Intervention Type: DEVICE; Name: Magpro X100 + Option; Assigned to Arm(s): magnetic seizure therapy | Intervention Type: DEVICE; Name: ThymatronSystem Ⅳ Electroconvulsive System; Assigned to Arm(s): electroconvulsive therapy | Intervention Type: OTHER; Name: treatment as usual (TAU); Assigned to Arm(s): electroconvulsive therapy, magnetic seizure therapy
C: Arm Label: MST; Type: EXPERIMENTAL; Interventions: Device: Magstim Theta | Arm Label: ECT; Type: ACTIVE_COMPARATOR; Interventions: Device: Thymatron | Intervention Type: DEVICE; Name: Thymatron; Assigned to Arm(s): ECT | Intervention Type: DEVICE; Name: Magstim Theta; Assigned to Arm(s): MST
D: Arm Label: Magnetic Seizure Therapy (MST); Type: EXPERIMENTAL; Interventions: Device: Magnetic Seizure Therapy | Arm Label: Electroconvulsive Therapy (ECT); Type: ACTIVE_COMPARATOR; Interventions: Device: Electroconvulsive Therapy | Intervention Type: DEVICE; Name: Magnetic Seizure Therapy; Assigned to Arm(s): Magnetic Seizure Therapy (MST) | Intervention Type: DEVICE; Name: Electroconvulsive Therapy; Assigned to Arm(s): Electroconvulsive Therapy (ECT)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Procalcitonin and Lung Ultrasonography Point-of-care Testing to Decide on Antibiotic Prescription in Patients With Lower Respiratory Tract Infection at Primary Care Level: Pragmatic Cluster Randomized Trial
Brief Summary: The study is randomized clustered pragmatic trial whose objective is to decrease unnecessary antibiotic prescription in adult patients with lower respiratory tract infection managed at primary care level in Switzerland, using a simple algorithm based on 2 point of care test results


Options:
A: Arm Label: Antibiotic use feedback letter 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Antibiotic use feedback letter | Arm Label: Antibiotic use feedback letter 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Antibiotic use feedback letter | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Antibiotic use feedback letter; Assigned to Arm(s): Antibiotic use feedback letter 1, Antibiotic use feedback letter 2
B: Arm Label: iCPR2 intervention; Type: EXPERIMENTAL; Interventions: Other: iCPR2 | Arm Label: iCPR2 control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: iCPR2; Assigned to Arm(s): iCPR2 intervention
C: Arm Label: UltraPro; Type: EXPERIMENTAL; Interventions: Diagnostic Test: UltraPro, Diagnostic Test: Blood sampling, Diagnostic Test: Naso-pharyngeal swab and sputum culture | Arm Label: Procalcitonin; Type: EXPERIMENTAL; Interventions: Diagnostic Test: Procalcitonin, Diagnostic Test: Blood sampling, Diagnostic Test: Naso-pharyngeal swab and sputum culture | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: Naso-pharyngeal swab and sputum culture | Intervention Type: DIAGNOSTIC_TEST; Name: UltraPro; Assigned to Arm(s): UltraPro | Intervention Type: DIAGNOSTIC_TEST; Name: Procalcitonin; Assigned to Arm(s): Procalcitonin | Intervention Type: DIAGNOSTIC_TEST; Name: Blood sampling; Assigned to Arm(s): Procalcitonin, UltraPro | Intervention Type: DIAGNOSTIC_TEST; Name: Naso-pharyngeal swab and sputum culture; Assigned to Arm(s): Procalcitonin, UltraPro, Usual Care
D: Arm Label: CRP-Control; Type: OTHER; Interventions: Other: No CRP will be measured onsite | Arm Label: CRP-A; Type: OTHER; Interventions: Other: CRP cut-off of 20mg/L. | Arm Label: CRP-B; Type: OTHER; Interventions: Other: CRP cut-off of 40mg/L. | Intervention Type: OTHER; Name: No CRP will be measured onsite; Assigned to Arm(s): CRP-Control | Intervention Type: OTHER; Name: CRP cut-off of 20mg/L.; Assigned to Arm(s): CRP-A | Intervention Type: OTHER; Name: CRP cut-off of 40mg/L.; Assigned to Arm(s): CRP-B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: FLUTicasone in Eosinophilic Esophagitis (FLUTE): A Randomized, Double-blind, Placebo-controlled, Dose-ranging, and Maintenance Study of APT-1011 in Subjects With Eosinophilic Esophagitis
Brief Summary: Eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus, characterized by eosinophilic infiltration and gastrointestinal symptoms. Swallowed, topically acting corticosteroids, such as fluticasone, appear to be effective in resolving acute clinical and pathological features of EoE.

APT-1011 is an orally disintegrating tablet (ODT) formulation of fluticasone propionate. This study is designed to compare the efficacy and safety of APT-1011 with placebo in adults with EoE for an initial 12-week treatment period, followed by an additional 40-week maintenance treatment phase. Histologic response, pharmacokinetics, and dysphagia will be assessed.


Options:
A: Arm Label: APT-1011 1.5 mg HS; Type: EXPERIMENTAL; Interventions: Drug: APT-1011, Drug: Placebo | Arm Label: APT-1011 1.5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: APT-1011 | Arm Label: APT-1011 3 mg HS; Type: EXPERIMENTAL; Interventions: Drug: APT-1011, Drug: Placebo | Arm Label: APT-1011 3 mg BID; Type: EXPERIMENTAL; Interventions: Drug: APT-1011 | Arm Label: Placebo BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: APT-1011; Assigned to Arm(s): APT-1011 1.5 mg BID, APT-1011 1.5 mg HS, APT-1011 3 mg BID, APT-1011 3 mg HS | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): APT-1011 1.5 mg HS, APT-1011 3 mg HS, Placebo BID
B: Arm Label: Oral cromolyn; Type: EXPERIMENTAL; Interventions: Drug: oral cromolyn sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: oral cromolyn sodium; Assigned to Arm(s): Oral cromolyn | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: RPC4046 Low Dose; Type: EXPERIMENTAL; Interventions: Drug: RPC4046 | Arm Label: RPC4046 High Dose; Type: EXPERIMENTAL; Interventions: Drug: RPC4046 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: RPC4046; Assigned to Arm(s): RPC4046 High Dose, RPC4046 Low Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: budesonide | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: budesonide | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: budesonide | Intervention Type: DRUG; Name: budesonide; Assigned to Arm(s): 2, 3, 4 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1

Answer: A